HongKong:1916701D

Novotech is Gold Sponsor at Biotech Showcase 2023

Retrieved on: 
화요일, 12월 20, 2022

SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.

Key Points: 
  • SYDNEY, AU, Dec 20, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO is proud to be Gold Sponsor at Biotech Showcase 2023.
  • Novotech CEO Dr. John Moller and experts from the Novotech US and Asia Pacific teams will be attending the conference.
  • Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions in Asia Pacific delivering exclusive benefits for sponsors.
  • The latest industry research publication by GlobalData and Novotech found almost 50% of new trials globally have sites in Asia Pacific.

Data Shows 50% of New Trials Have Sites in Asia Pacific

Retrieved on: 
일요일, 12월 18, 2022

SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.

Key Points: 
  • SYDNEY, AU, Dec 15, 2022 - (ACN Newswire) - Novotech, the Asia Pacific centered biotech specialist CRO said the latest industry research publication by GlobalData and Novotech found almost 50% of new trials had sites in Asia Pacific.
  • According to the new publication titled "State of the Global Biotech Landscape: Where the Opportunities Lie", demand for Asia Pacific trial sites is strong with almost half of the more than 27,000 clinical trials initiated in 2021 having sites in Asia Pacific.
  • The data shows almost 12,900 of the new trials had sites in Asia Pacific.
  • - Phases I and II were dominated by Asia Pacific, which served as a trial location in 57% and 49% of trials, respectively.